1. HOME
2. Research Insight
3. Thermo Fisher Scientific (US), Becton, Dickinson and Company (US) and Agilent Technologies (US) Cell Analysis Market

The global cell analysis market is projected to reach USD 28.6 Billion by 2027 from USD 17.7 Billion in 2022, at a CAGR of 10.1% during the forecast period. One of the key driving factors of the cell analysis market includes elevating demand for cell-based assays in drug discovery. As compared to biochemical or non-cell-based assays, high biological relevance is observed in cell-based assays. This aids in predicting complexities of a therapeutic response within a biological system with efficiency. Thus, these assays enhance the drug discovery and development process, minimizing the time of product-to-market process for novel help therapeutics.

Cell analysis market is fragmented and competitive in nature, several market players are adopting strategies to sustain market competition. The company offerings range from, cell analysis & imaging products, flow cytometry products & services, and other analytical solutions that have larger geographic reach along with high product flexibility. Prominent players in the global cell analysis market are Danaher (US), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), General Electric (US), Merck KGaA (US), Agilent Technologies (US), Olympus Corporation (Japan), Miltenyi Biotec (US), Bio-Rad Laboratories (US), BioStatus Limited (UK), Fluidigm Corporation (US), NanoCellect Biomedical (US), Cell Biolabs (US), Creative Bioarray (US), Meiji Techno (US), Promega Corporation (US), PerkinElmer (US), Tecan Trading AG (Switzerland), CELLINK (US), QIAGEN (Germany), Corning Incorporated (US), 10x Genomics (US), and Illumina (US).

To know about the assumptions considered for the study download the pdf brochure

THERMO FISHER SCIENTIFIC (US)

Thermo Fisher Scientific (US) ranked first in terms of revenue share in the cell analysis market, accounting for the largest market share in 2021. Company’s dominant share in this market is attributed to its robust product portfolio coupled with strong brand image. Thermo Fisher Scientific observed strategic product launches, acquisitions, collaborations, and expansions in the past 2-3 years to maintain its market position. For instance, in May 2022, Thermo Fisher Scientific collaborated with Charles River Laboratories (US) and Multiply Labs (US) to aid in the automation of cell therapy production process. Multiply Labs (US) is engaged in robotics whereas Thermo Fisher will assist in quality control testing in this strategic collaboration.

AGILENT TECHNOLOGIES (US)

Agilent Technologies (US) accounted for the second-largest share in the cell analysis market in 2021. The company develops cell analysis tools that can be applied across several cell health monitoring applications, including cell signaling pathways, general cell function, and behavior through metabolic profile analysis and real-time cellular impedance measurements. Agilent’s portfolio caters to the critical steps in cell-based research experiments. The cell analysis product offerings include cell analysis plate-based assays, flow cytometers, real-time cell analyzers, microplate readers, cell imaging systems, and related consumables. The high demand for Agilent’s cell analysis products among academic institutes and pharmaceutical & biopharmaceutical companies is the key contributor to the company’s significant share in the cell analysis market.

BECTON, DICKINSON AND COMPANY (US)

BD (US) is the third-largest player in the cell analysis market in 2021. BD displays a diverse product portfolio for flow cytometry-based cell analysis. Flow cytometry-based cell analysis product offerings range from advancement instruments to simple kits and accessories. BD has a strong presence across the globe through its robust distribution network across North America, Europe, the Asia Pacific, Europe, the Middle East, and Africa. BD has launched several technologically advanced flow cytometry products in the past few years, strategic product launches have helped BD maintain its market position in this fragmented market. Some of the strategic product launches done by the company in the past few years include BD FACSymphony S6 cell sorter, BD FACSLyric flow cytometer system, and Precise WTA reagents. In addition, in April 2022, the company introduced a latest addition to its flow cytometry reagents portfolio, namely, BD Horizon RealYellow 586 Reagents. These reagents enhance data resolution from samples to accelerate discovery and drug development and are developed via their novel dye technology incorporating AI guidance.

Related Reports:

Cell Analysis Market by Product & Service (Reagents & Consumables, Instruments), Technique (Flow Cytometry, High Content Screening), Process (Single-cell Analysis), End User (Pharmaceutical and Biotechnology Companies) - Global Forecast to 2027

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]